Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Automated Low-Flow Pump Removes Ascites

By HospiMedica International staff writers
Posted on 28 Jul 2011
An innovative pump system removes refractory ascites due to liver cirrhosis as it forms by transferring it to the bladder, where it is eliminated through normal urination.

The ALFApump system is indicated for the management of refractory and recurrent ascites due to liver cirrhosis, in which massive and uncontrolled fluid accumulation occurs in the abdominal cavity. More...
The system is comprised of a subcutaneously implanted battery powered pump that is connected to a catheter placed in the abdominal cavity, and another catheter connected to the bladder. The system automatically and continually collects fluid as it forms in the abdominal cavity and moves it to the bladder, where it is eliminated through normal urination; a single charge of the system is enough to move five liters of ascites.

The ALFApump is recharged wirelessly through the skin, and can also be wirelessly programmed by the attending physician. Implantation can be performed under local or general anesthesia (GA), and takes about 45 minutes. The system is a product of Sequana Medical (Zug, Switzerland), and has received the Conformite Europeenne (CE) marking.

“This is a major milestone both for our company and for patients with refractory ascites,” said Noel Johnson, MD, CEO of Sequana Medical. “For patients, the treatment options for refractory ascites have been very limited and carried significant risks and side effects. The ALFApump System offers a new treatment tool, which can improve patient quality of life while also reducing hospitalizations. It is a cost-effective solution and we believe over time it will become the preferred option for patients, physicians, and payers.”

“The benefits of the ALFApump System are entirely aligned with the goals of patients, physicians and payers,” added Dan Rose, VP of commercial operations at Sequana Medical. “The system is designed to offer patients better clinical outcomes and quality of life while eliminating the requirement for repeated expensive and burdensome invasive procedures.”

Refractory ascites occurs when patients with ascites no longer respond to medical therapy, a condition that affects over 100,000 patients in Europe and the United States every year; that number is growing at approximately 10% a year due to the accelerating incidence of hepatitis- and obesity-related liver disease. The primary treatment for ascites is paracentesis, a procedure in which a large bore needle is inserted into the patient's abdomen to remove between 5-10 liters of ascites that has accumulated over a period of a week or two.

Related Links:

Sequana Medical




Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Head Rest
Medifa 61114_3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.